Cargando…

Ribociclib: a valuable addition to treatment options in breast cancer?

Detalles Bibliográficos
Autor principal:	Bartsch, Rupert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729298/ https://www.ncbi.nlm.nih.gov/pubmed/29302367 http://dx.doi.org/10.1136/esmoopen-2017-000246

Ejemplares similares

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
por: Pribnow, Allison, et al.
Publicado: (2022)

Cost‐effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore
por: Loke, Lydia, et al.
Publicado: (2020)

Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy
por: O’Shaughnessy, Joyce
Publicado: (2020)

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
por: Bellet, Meritxell, et al.
Publicado: (2019)

Open Access and an Additional Publishing Option
por: Bhattacharya, Sanjoy
Publicado: (2012)

Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib
por: Germa, C., et al.
Publicado: (2017)

Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil
por: Buehler, Anna Maria, et al.
Publicado: (2022)

Subcutaneous Immunoglobulins are a Valuable Treatment Option in Myasthenia Gravis
por: Garnero, Martina, et al.
Publicado: (2018)

Ribociclib Hybrid Lipid–Polymer Nanoparticle Preparation and Characterization for Cancer Treatment
por: Al-Shdefat, Ramadan, et al.
Publicado: (2023)

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
por: Byers, Kristina F.
Publicado: (2021)

The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer
por: Iida, Masafumi, et al.
Publicado: (2019)

A Valuable Premium
Publicado: (1884)

Ribociclib Induced Photosensitive Skin Lesions
por: Verma, Vaishnavi, et al.
Publicado: (2022)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Valuable New Books
Publicado: (1877)

Cost-effectiveness of Ribociclib in HER2- negative breast cancer: A synthesis of current evidence
por: Alotaibi, Wedad H., et al.
Publicado: (2022)

Photoallergic dermatitis and vitiligo-like lesion in a patient with metastatic breast cancer using ribociclib
por: Menteşoğlu, Dilek
Publicado: (2023)

Ribociclib-induced Vitiligo: a Case Report
por: Silvestre Torner, Nicolás, et al.
Publicado: (2022)

This is a valuable editorial on assertiveness!
por: D’Eon, Marcel F.
Publicado: (2020)

Pulmonary Artery Banding is Still a Valuable Option
por: Durandy, Yves
Publicado: (2013)

Valuable Contributions
Publicado: (1883)

Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
por: Yang, Jiangping, et al.
Publicado: (2020)

Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
por: Odabas, Hatice, et al.
Publicado: (2023)

Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
por: Coffman, Lan G., et al.
Publicado: (2022)

Total Thyroidectomy with Central Node Dissection is a Valuable Option in Papillary Thyroid Cancer Treatment
por: Pastorčić Grgić, Marija, et al.
Publicado: (2020)

A Valuable Series
Publicado: (1916)

Is correcting exposure misclassification bias an additional option in meta-analyses?
por: Kim, Ki Eun
Publicado: (2021)

A New and Valuable Diagnostic System
Publicado: (1885)

Adjuvant Chemotherapy, a Valuable Alternative Option in Selected Patients with Cervical Cancer
por: Li, Shuang, et al.
Publicado: (2013)

Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries
por: Subotic, Dragan, et al.
Publicado: (2018)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer
por: Mayayo-Peralta, Isabel, et al.
Publicado: (2021)

Valuable Surgical Discovery
Publicado: (1859)

SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma
por: Moreaux, Jerome
Publicado: (2014)

Our Valuable Contributors: Reviewers of 2016
Publicado: (2017)

Our Valuable Contributors: Reviewers of 2013
por: Lee, Yunhwan
Publicado: (2014)

Our Valuable Contributors: Reviewers of 2014
por: Cho, Sung-il
Publicado: (2015)

Our Valuable Contributors: Reviewers of 2015
por: Cho, Sung-il
Publicado: (2016)

Our Valuable Contributors: Reviewers of 2017
por: Cho, Sung-il
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mv2hha86cdv3if1vellh9sfcrk